Northshore University Health System

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Aortic stenosis1 trial
• Chronic spontaneous urticaria1 trial
• Coronary artery disease1 trial
• High blood pressure1 trial
• Long COVID and ME/CFS1 trial
• Multiple system atrophy1 trial
• Myasthenia gravis1 trial
• Postural tachycardia syndrome (POTS)1 trial
• Pulmonary arterial hypertension1 trial
• Type 2 diabetes1 trial

Phase

• Phase 33 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Completed3 trials
• Active, not recruiting2 trials
• Recruiting2 trials

Lead sponsor

• argenx1 trial
• Cleerly, Inc.1 trial
• Kardigan, Inc.1 trial
• Novartis Pharmaceuticals1 trial
• Regeneron Pharmaceuticals1 trial
• and 2 more

Running trials

• Recruiting

  Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

  NCT07001800· Phase 2/3· Kardigan, Inc.· Source

• Recruiting

  A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

  NCT06112418· Cleerly, Inc.· Source

  Contact: Amit K. Pursnani, MD

• Active, not recruiting

  Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

  NCT05696717· Phase 3· Theravance Biopharma· Source

• Active, not recruiting

  A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

  NCT05070858· Phase 3· Regeneron Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Aortic stenosis1 recruiting
• Coronary artery disease1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

  NCT05776225· United Therapeutics· Source

• Completed

  Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

  NCT05633407· Phase 2· argenx· Source

• Completed

  A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines

  NCT05032157· Phase 3· Novartis Pharmaceuticals· Source